Int J Angiol
DOI: 10.1055/s-0040-1722739
Invited Article

Medical and Revascularization Management of Stable Ischemic Heart Disease: An Overview

Qais Radaideh
1  Midwest Cardiovascular Research Foundation, Davenport, Iowa
2  University of Iowa Hospitals and Clinics, Iowa City
,
Nicolas W. Shammas
1  Midwest Cardiovascular Research Foundation, Davenport, Iowa
2  University of Iowa Hospitals and Clinics, Iowa City
,
Ghassan E. Daher
3  SSM Health Saint Louis University Hospital, St. Louis, Missouri
,
Rayan Jo Rachwan
4  Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
› Author Affiliations
Funding N.W.S. receives educational and research grants from Boston Scientific, Bard, Intact Vascular, VentureMed Group and is on the speaker bureau of Janssen, Boehringer Ingelheim, Novartis, and Zoll Medical.

Abstract

Stable ischemic heart disease (SIHD) affects approximately 10 million Americans with 500,000 new cases diagnosed each year. Patients with SIHD are primarily managed in the outpatient setting with aggressive cardiovascular risk factor modification via medical therapy and lifestyle changes. Currently, this approach is considered as the mainstay of treatment. The recently published ISCHEMIA trial has established the noninferiority of medical therapy in comparison to coronary revascularization in patients with moderate to severe ischemia. Percutaneous coronary intervention is currently recommended for patients with significant left main disease, large ischemic myocardial burden, and patients with severe refractory angina despite maximal medical therapy.



Publication History

Publication Date:
21 January 2021 (online)

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA